JP2024527322A - がんを治療するための組成物および方法 - Google Patents

がんを治療するための組成物および方法 Download PDF

Info

Publication number
JP2024527322A
JP2024527322A JP2023580691A JP2023580691A JP2024527322A JP 2024527322 A JP2024527322 A JP 2024527322A JP 2023580691 A JP2023580691 A JP 2023580691A JP 2023580691 A JP2023580691 A JP 2023580691A JP 2024527322 A JP2024527322 A JP 2024527322A
Authority
JP
Japan
Prior art keywords
polynucleotide
antigen
antibody
cancer
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527322A5 (enExample
Inventor
イライアス クイジャーノ
ピーター グレイザー
ブルース シー． ターナー
デール ルードウィック
ヴェヌゴパラレディ ボミレディヴェンカタ
ルイーザ エスコバル－オヨス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2024527322A publication Critical patent/JP2024527322A/ja
Publication of JP2024527322A5 publication Critical patent/JP2024527322A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023580691A 2021-07-02 2022-07-05 がんを治療するための組成物および方法 Pending JP2024527322A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163217926P 2021-07-02 2021-07-02
US63/217,926 2021-07-02
US202163218970P 2021-07-07 2021-07-07
US63/218,970 2021-07-07
US202163239372P 2021-08-31 2021-08-31
US63/239,372 2021-08-31
US202263297542P 2022-01-07 2022-01-07
US202263297538P 2022-01-07 2022-01-07
US63/297,542 2022-01-07
US63/297,538 2022-01-07
PCT/US2022/036143 WO2023278897A1 (en) 2021-07-02 2022-07-05 Compositions and methods for treating cancers

Publications (2)

Publication Number Publication Date
JP2024527322A true JP2024527322A (ja) 2024-07-24
JP2024527322A5 JP2024527322A5 (enExample) 2025-07-14

Family

ID=84690676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580691A Pending JP2024527322A (ja) 2021-07-02 2022-07-05 がんを治療するための組成物および方法

Country Status (6)

Country Link
EP (1) EP4362984A1 (enExample)
JP (1) JP2024527322A (enExample)
KR (1) KR20240043747A (enExample)
AU (1) AU2022302143A1 (enExample)
IL (1) IL309662A (enExample)
WO (1) WO2023278897A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2025097000A1 (en) * 2023-11-01 2025-05-08 Yale University Antibody-based methods for treating polycystic kidney disease
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
JP2000507225A (ja) 1996-03-08 2000-06-13 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア ｍａｂ ３Ｅ１０ ならびにその突然変異体および／または機能性フラグメントを使用する送達システム
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
DK2176408T5 (en) 2008-01-31 2015-12-14 Curevac Gmbh Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS.
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
US20110184045A1 (en) 2008-06-30 2011-07-28 Gunther Hartmann Silencng and rig-i activation by dual function oligonucleotides
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013064584A1 (en) 2011-10-31 2013-05-10 Riboxx Gmbh Double-stranded RNA for immunostimulation
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2014169049A1 (en) 2013-04-09 2014-10-16 Duke University 2' fluoro-modified rnas as immunostimulators
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
AU2015204446A1 (en) 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
CA2995673A1 (en) 2014-08-27 2016-03-03 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
DE102015008536A1 (de) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
LT3386541T (lt) 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
WO2017173427A1 (en) 2016-04-01 2017-10-05 Vycellix Inc Novel rna construct and methods of use thereof for enhancing the therapeutic effects of cytotoxic cells and stem cells
US11382966B2 (en) 2017-03-24 2022-07-12 Rigontec Gmbh Method for designing RIG-I ligands
EP3655432A4 (en) 2017-07-17 2021-04-14 Nucleus Therapeutics Pty Ltd BINDING PROTEINS 1
WO2019143297A1 (en) 2018-01-17 2019-07-25 Nanyang Technological University Immunomodulatory small hairpin rna molecules
WO2019152884A1 (en) 2018-02-02 2019-08-08 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
JP7366057B2 (ja) 2018-04-19 2023-10-20 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
EP3810151B1 (en) 2018-06-20 2025-08-06 Yale University Rig-i agonists and treatments using same
EP3990635A1 (en) 2019-06-27 2022-05-04 Rigontec GmbH Design method for optimized rig-i ligands
WO2021042060A1 (en) * 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
EP4045656A1 (en) 2019-10-16 2022-08-24 SomaLogic Operating Co., Inc. Nucleic acid compounds that bind to retinoic acid-inducible gene i protein
CN116529266A (zh) * 2020-08-31 2023-08-01 耶鲁大学 用于将核酸递送到细胞的组合物和方法
AU2021390561A1 (en) * 2020-12-04 2023-06-22 Yale University Compositions and methods for delivery of nucleic acids to cells

Also Published As

Publication number Publication date
WO2023278897A9 (en) 2023-03-16
AU2022302143A1 (en) 2024-01-18
EP4362984A1 (en) 2024-05-08
KR20240043747A (ko) 2024-04-03
AU2022302143A2 (en) 2025-10-02
IL309662A (en) 2024-02-01
WO2023278897A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
US20230303719A1 (en) Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
JP7542441B2 (ja) 癌を治療するための方法及び組成物
JP2024527322A (ja) がんを治療するための組成物および方法
CN114258430A (zh) 使用融合蛋白进行tcr重编程的组合物和方法
CN110753756A (zh) 免疫调节性多核苷酸及其应用
US20220273720A1 (en) Lymphodepletion dosing regimens for cellular immunotherapies
JP2024500303A (ja) 細胞への核酸の送達のための組成物及び方法
JP2022512922A (ja) キメラ抗原受容体記憶様（ｃａｒｍｌ）ｎｋ細胞ならびにその産生および使用方法
JP2023544970A (ja) 細胞への核酸の送達のための組成物及び方法
WO2019081591A1 (en) NK CELLS AND LYMPHOCYTES AND USES THEREOF
JP2025525864A (ja) ナチュラルキラー細胞の機能を増強するための標的遺伝子の遺伝子編集
JP2024532621A (ja) がんを治療するための組成物および方法
JP2024527322A5 (enExample)
CA3226130A1 (en) Compositions and methods for treating cancers
CN117897178A (zh) 用于治疗癌症的组合物和方法
JP2023532347A (ja) キメラ抗原受容体の緊張性シグナル伝達を減少させる方法および組成物
US12460208B2 (en) Immunomodulatory polynucleotides and uses thereof
WO2026039779A1 (en) Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding
WO2025029625A1 (en) Compositions and methods for programmed death ligand receptor (pd-l1) expression
WO2024240248A1 (zh) 用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
CN120359048A (zh) 用于细胞特异性表达的组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250704

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20251029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251029